Combining Liposomal Doxorubicin and Gemcitabine for Ovarian Cancer Treatment
Author Information
Author(s): D'Agostino G, Ferrandina G, Ludovisi M, Testa A, Lorusso D, Gbaguidi N, Breda E, Mancuso S, Scambia G
Primary Institution: Catholic University of the Sacred Heart
Hypothesis
The combination of gemcitabine and liposomal doxorubicin may improve treatment outcomes in recurrent ovarian cancer patients.
Conclusion
The combination of gemcitabine and liposomal doxorubicin has shown promising response rates in recurrent ovarian cancer patients.
Supporting Evidence
- Overall response rate was 34.3%, with complete responses at 10.4%.
- Platinum-sensitive patients had a higher response rate of 45.2%.
- Severe haematological toxicity was observed in 42.8% of patients.
Takeaway
Doctors tested two cancer drugs together to see if they could help women with ovarian cancer that came back after treatment, and they found that many women responded well.
Methodology
This was a noncomparative phase II study involving patients with recurrent ovarian cancer who received a combination of liposomal doxorubicin and gemcitabine.
Potential Biases
Potential biases may arise from the nonrandomized design and the specific eligibility criteria.
Limitations
The study was noncomparative and involved a relatively small sample size.
Participant Demographics
Median age of participants was 59 years, with a range from 25 to 76 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 23.0–45.6
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website